FDA Investigator Caryn M Everly

Caryn M Everly has conducted inspections on 19 sites in 3 countries as of 19 Feb 2002. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
19
Last Inspection Date:
19 Feb 2002
Investigator Role:
FDA Investigation Participant
Redica ID:
100006735
Countries of Inspections:
United States of America, Denmark, France
FDA Investigators that have inspected at least one site in common with Caryn M Everly:
Adam R Cooke, Aikaterini Alexaki, Alan P Kurtzberg, Alexandra B Pitkin, Alyson C Tanner, Amalia C Himaya, Amanda L Fyles, Amir Alavi, Andrew S Limson, Angela Shepas, Arie C Menachem, Arsen Karapetyan, Ashar P Parikh, Babajide Michael Osunsanmi, Benjamin S Liao, Bichsa T Tran, Binh T Nguyen, Brian J Ryan, Brien C Fox, Bryan A Galvez, Bryan L Mcguckin, Burnell M Henry, Calvin B Koerner, Carl Lee, Carla J Lundi, Carrie A Hughes, Caryn M Mcnab, Cassandra L Abellard, Cathleen A Carr Sharpe, CDR Rochelle B Young, RPh, MSA, Chava Kimchi Sarfaty, PhD, Chelsea N Sealey, Christopher D Leach, Christopher R Czajka, Claudia Mperez Kasmarski, Comyar Shoghi, Cynthia J Lee, MS, Daniel R Solis, Daniel W Cline, David Serrano, Deborah A Greco, Dejon N Harris, Diana M Rand, Diane Cvan Leeuwen, Dr. Mark J Seaton, PhD, Dyana K Stone, Eileen A Liu, Emest F Bizjak, Evelyn Wong, Frederick L Fricke, Gene D Arcy, Geraldine D Sanders, Greg K Keshishyan, Gregory A Berg, Jacqueline Mdiaz Albertini, James P Stumpff, Jane S Wernberg, Janet D Blount, Jeffery A Johnson, Jeffrey P Raimondi, Jennifer M Gogley, Jinnie Kokiatkulkij, Jocelyn E Massey, Jocelyn E Sparks, Joe X Phillips, Joey V Quitania, John A Gonzalez, Jolanna A Norton, Joseph X Phillips, Joyce A Rockwell, Juanita Banuelos, Julie A Rorberg, Julie A Stocklin, Ka L Wong, Karen A Wolnik, Kari M Johansen, Katherine E Jacobitz, Kathy Chiu, Kathy Kuo, Kelley, Kelvin Cheung, Kelvin X Sanders, Kham Phommachanh, Khoa Nathanv Tran, Kim Lthomas Cruse, Lakecha N Lewis, Lewis K Antwi, Liming Zhang, Linda F Murphy, Linda Thai, Ling Yu L Liu, Lisa Shin, Louis B Cencetti, Lucas B Leake, Marco S Esteves, Marcus F Yambot, Marie Falcone, Marie T Falcone, Mariza M Jafary, Mark A Tucker, Mark C Saale, Matthew J Johnson, Maxyne T Lam, Michael D Garcia, Michael Shanks, MS, Michele L Forster, PhD, Michelle J Hines, Miguel A Martinez Perez, Mihaly S Ligmond, Minh D Phan, Mra Munizn, Natalya M Ananyeva, Nicholas L Hunt, Nicholas Obiri, PhD, Omotunde O Osunsanmi, Paquita F Segarra, Paula A Trost, Peter C Chow, Prabhu P Raju, Prasad Peri, PhD, Randall N Johnson, Raymond T Oji, Rebecca K Olin, Richard C Chiang, Richmond K Yip, Robert C Coleman, Robert D Tollefsen, Robert Jennings, Roman T Drews, PhD, Rumany C Penn, PharmD, S Lori Brown, PhD MPH, Saied A Asbagh, Sandra S Saniga, Sangeeta M Khurana, PhD, Santiago Gallardo Johnson, Sarah A Hassas, Selene T Torres, Shannon B Ruelle, Simone E Pitts, Sonya L Karsik, RAC, Sparky L Bartee, Stephanie A Slater, MS, Steven E Porter, Jr, Sudipan Karmakar, Sue Lee Chan, Susan Yu, Svetlana A Shestopal, Taichun Qin, PhD, Tamala P Magee, Terri L Dodds, Theresa Kirkham (NMI), Thomas J Arista, Thomas R Beilke, Timothy T Kapsala, Tony J Wu, Tracey T Duong, Truong Xuan Nguyen (Andy), Uttaniti Limchumroon (Tom), Valerie L Whipp, Vashti E Bocker, Vickie L Anderson, Virgilio F Pacio, CSO, Walden H Lee, William J Leonard, Yumi J Hiramine, Yvette Mlacour Davis, Yvonne T Lacour, Zachary A Bogorad

Caryn M Everly's Documents

Publish Date Document Type Title
June, 2001 FDA 483 Bachem Americas, Inc. - Form 483, 2001-06-08
September, 2000 EIR International Medication Systems, Ltd. - EIR, 2000-09-21
September, 2001 EIR H. Lundbeck A/S - EIR, 2001-10-04
January, 2001 FDA 483 Banner Pharmacaps Inc. - Form 483, 2001-01-23
September, 2001 EIR H. Lundbeck A/S - EIR, 2001-10-04
May, 2001 EIR Aventis Laboratories - EIR, 2001-05-31
February, 2001 FDA 483 Response Kindeva Drug Delivery L.P. - Form 483R, 2001-03-07
December, 2000 FDA 483 Response Kindeva Drug Delivery L.P. - Form 483R, 2000-12-20
September, 2000 EIR Watson Laboratories, Inc. - EIR, 2000-09-14
December, 2000 EIR Kindeva Drug Delivery L.P. - EIR, 2000-12-13
February, 2001 FDA 483 Kindeva Drug Delivery L.P. - Form 483, 2001-02-20
September, 2000 EIR Teva Parenteral Medicines, Inc. - EIR, 2000-09-18
September, 2001 FDA 483 Response H. Lundbeck A/S - Form 483R, 2001-10-11
July, 2000 FDA 483 Carlsbad Technology, Inc. - Form 483, 2000-07-28
March, 2002 FDA 483 Abraxis Bioscience LLC - Form 483, 2002-03-01
October, 2000 FDA 483 MD Pharmaceuticals aka Celltech Manufacturing - Form 483, 2000-10-24
June, 2001 EIR Bachem Americas, Inc. - EIR, 2001-06-08
February, 2001 EIR Kindeva Drug Delivery L.P. - EIR, 2001-02-20
August, 2001 EIR Person and Covey - EIR, 2001-08-20
June, 2000 FDA 483 Allergan Sales, LLC - Form 483, 2000-06-05
August, 2001 FDA 483 Person and Covey - Form 483, 2001-08-20
July, 2000 EIR Carlsbad Technology, Inc. - EIR, 2000-07-28
July, 2001 EIR BAXALTA US INC. - EIR, 2001-07-13
December, 2000 FDA 483 Kindeva Drug Delivery L.P. - Form 483, 2000-12-13
October, 2000 EIR MD Pharmaceuticals aka Celltech Manufacturing - EIR, 2000-10-24
July, 2000 FDA 483 Response Carlsbad Technology, Inc. - Form 483R, 2000-08-25
March, 2001 EIR PYRAMID Laboratories, Inc. - EIR, 2001-03-14
February, 2000 FDA 483 Teva Parenteral Medicines, Inc. - Form 483, 2000-02-25
February, 2000 EIR Teva Parenteral Medicines, Inc. - EIR, 2000-02-25
January, 2001 EIR Banner Pharmacaps Inc. - EIR, 2001-01-23

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more